Asymmetric deep cerebral venous filling predicts poor outcome of acute basilar artery occlusion after endovascular treatment
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14513 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Huiyuan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical Co…. Hauptthemen laut MEDLINE: Arterial Occlusive Diseases, Cerebral Veins, Brain Edema, Endovascular Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Postgraduate Research Innovation Program of Bengbu Medical College, Zhejiang Provincial Science and Technology Department Foundation.
Abstract (Originalsprache)
Objective
To explore the relationship between asymmetric deep cerebral venous (ADCV) filling and poor outcomes after endovascular treatment (EVT) in patients with acute basilar artery occlusion (ABAO).
Methods
ABAO patients were selected from a prospectively collected data at our center. The DCV filling was evaluated using computed tomography perfusion (CTP)‐derived reconstructed 4D‐DSA or mean venous map. ADCV filling was defined as the internal cerebral vein (ICV), thalamostriate vein (TSV), or basal vein of Rosenthal (BVR) presence of ipsilateral filling defects or delayed opacification compared to the contralateral side. Poor prognosis was defined as a modified Rankin scale score >3 at the 90‐day follow‐up.
Results
A total of 90 patients were enrolled in the study, with a median Glasgow Coma Scale of 6, 46 (51.1%) showed ADCV filling, 59 (65.6%) had a poor prognosis, and 27 (30.7%) had malignant cerebellar edema (MCE). Multivariate adjusted analysis revealed significant associations between asymmetric TSV and poor prognosis (odds ratio, 9.091, p = 0.006); asymmetric BVR (OR, 9.232, p = 0.001) and asymmetric ICV (OR, 4.028, p = 0.041) were significantly associated with MCE.
Conclusion
Preoperative ADCV filling is an independent influencing factor for the poor outcome after EVT in ABAO patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
- School of Clinical Medicine, Graduate School, Bengbu Medical College, Bengbu, China.
- The Second Clinical Medical College, Zhejiang Traditional Chinese Medicine University, Hangzhou, China.
- Alberta Institute, Wenzhou Medical University, Wenzhou, China.
- Department of Quality Management, Zhejiang Provincial People's Hospital, Hangzhou, China.
- School of Medicine and Public Health, University of Newcastle, New South Wales, Newcastle, Australia.
ORCID-Profile: Huiyuan Wang
Förderung
- The Postgraduate Research Innovation Program of Bengbu Medical College
- Zhejiang Provincial Science and Technology Department Foundation
Zitieren
APA
Wang, H., Shen, P., Yu, X., Shang, Y., Xu, J., Chen, X., Tan, M., Lin, L., Parsons, M., Zhang, S., & Geng, Y. (2024). Asymmetric deep cerebral venous filling predicts poor outcome of acute basilar artery occlusion after endovascular treatment. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14513
Vancouver
Wang H, Shen P, Yu X, Shang Y, Xu J, Chen X, et al. Asymmetric deep cerebral venous filling predicts poor outcome of acute basilar artery occlusion after endovascular treatment. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14513
BibTeX
@article{Wang2024,
author = {Wang, Huiyuan and Shen, Panpan and Yu, Xinyue and Shang, Yafei and Xu, Jie and Chen, Xinyi and Tan, Mingming and Lin, Longting and Parsons, Mark and Zhang, Sheng and Geng, Yu},
title = {Asymmetric deep cerebral venous filling predicts poor outcome of acute basilar artery occlusion after endovascular treatment},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14513}
}
EUVIMED